SCHEMBL570870

SCHEMBL570870

C1=CNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17319722 0.73
Naphthalene SCHEMBL11705897 0.73 CYP2A6 (0.53)
SCHEMBL2950040 0.73
SCHEMBL2121178 0.73
SCHEMBL740269 0.73
SCHEMBL10152907 0.73
Charcoal, Activated SCHEMBL7286110 0.73
SCHEMBL16915533 0.73
SCHEMBL235816 0.73
SCHEMBL9276201 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient YUYU PHARMA, INC. (KR) 2024-07-16 US disclosed
WO-2024101386-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS 中外製薬株式会社 2024-05-16 WO disclosed
WO-2024101402-A1 PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS 中外製薬株式会社 2024-05-16 WO disclosed
US-20240158446-A1 CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-16 US disclosed
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-09 US disclosed
US-20240124517-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-04-18 US disclosed
WO-2024080333-A1 METHOD FOR PRODUCING N-SUBSTITUTED AMINO ACID RESIDUE-CONTAINING CYCLIC PEPTIDE COMPOUND 中外製薬株式会社 2024-04-18 WO disclosed
US-20240117400-A1 T CELLS WITH REDUCED SURFACE FUCOSYLATION AND METHODS OF MAKING AND USING THE SAME SEAGEN INC (US) 2024-04-11 US disclosed
US-20240067674-A1 METHOD FOR LOADING AMINO ACID ON RESIN FOR SOLID-PHASE SYNTHESIS CHUGAI PHARMACEUTICAL CO LTD (JP) 2024-02-29 US disclosed
EP-4316503-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-07 EP disclosed
EP-1176962-A2 LIPOSOME COMPOSITIONS FOR IMPROVED DRUG RETENTION Alza Corporation (US) 2002-02-06 EP disclosed
EP-1083881-A2 LIPOSOME COMPOSITION AND METHOD FOR ADMINISTERING A QUINOLONE ALZA Corporation (US) 2001-03-21 EP disclosed
WO-2000066126-A2 LIPOSOME COMPOSITIONS FOR IMPROVED DRUG RETENTION ALZA CORPORATION (US) 2000-11-09 WO disclosed
US-6034118-A ENZYME INHIBITOR GILEAD SCIENCES, INC. (US) 2000-03-07 US disclosed
US-5972379-A LIPOSOMES HAVING A SURFACE COATING OF HYDROPHILIC POLYMER CHAINS AND AN ENTRAPPED CIPROFLOXACIN-AMINO ACID CONJUGATE, USEFUL FOR TREATING THE BACTERIAL INFECTIONS SEQUUS PHARMACEUTICALS, INC. (US) 1999-10-26 US disclosed
WO-1999051202-A2 QUINOLONE CONTAINING LIPOSOMES AND THEIR USE AS ANTIBACTERIAL AGENTS SEQUUS PHARMACEUTICALS, INC. (US) 1999-10-14 WO disclosed
US-5811450-A DIAGNOSIS, TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 1998-09-22 US disclosed
US-5705524-A ENZYME INHIBITORS; VIRICIDES GILEAD SCIENCES, INC. (US) 1998-01-06 US disclosed
EP-0789695-A2 THIEPANE COMPOUNDS INHIBITING AND DETECTING HIV PROTEASE GILEAD SCIENCES, INC. (US) 1997-08-20 EP disclosed
WO-1996014314-A2 THIEPANE COMPOUNDS INHIBITING AND DETECTING HIV PROTEASE GILEAD SCIENCES, INC. (US) 1996-05-17 WO disclosed